Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.54 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.47 |
| ▸ | ATR | Q13535 | 1/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3956002 | 0.93 | GPR119 (0.55) | GPR119NR3C1USP30PIK3CAMTOR | |
| SCHEMBL3955027 | 0.91 | GPR119 (0.54) | GPR119NR3C1USP30PIK3CAMTOR | |
| SCHEMBL5034318 | 0.89 | USP30 (0.50) | GPR119USP30PIK3CAPIK3CGJAK2 | |
| SCHEMBL14048942 | 0.86 | JAK1 (0.42) | GPR119PIK3CAMTORJAK2JAK1 | |
| SCHEMBL3959085 | 0.84 | JAK1 (0.45) | MTORJAK2JAK1CYP3A4 | |
| SCHEMBL3948591 | 0.84 | PIK3CA (0.48) | PIK3CAMTORJAK2JAK1 | |
| SCHEMBL3946682 | 0.82 | USP30 (0.51) | GPR119USP30PIK3CAPIK3CGJAK1 | |
| SCHEMBL3957427 | 0.82 | JAK1 (0.44) | NR3C1JAK2JAK1CYP3A4 | |
| SCHEMBL3949881 | 0.81 | IKBKB (0.50) | JAK2JAK1CYP3A4 | |
| SCHEMBL3950327 | 0.81 | USP30 (0.49) | GPR119USP30PIK3CAPIK3CGJAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262040-A1 | novel indazole carboxamide derivatives for inflammatory and tissue repair disorders like rheumatoid arthritis, asthma, and COPD; kinase inhibitors in particular IKK2; 1,1-dimethylethyl-4-[4-(aminocarbonyl)-6-phenyl-1H-indazol-1-yl]-1-piperidinecarboxylate; intermediates | SMITHKLINE BEECHAM CORPORATION | 2008-10-23 | — | — | US | claimed |
| US-20080262040-A1 | novel indazole carboxamide derivatives for inflammatory and tissue repair disorders like rheumatoid arthritis, asthma, and COPD; kinase inhibitors in particular IKK2; 1,1-dimethylethyl-4-[4-(aminocarbonyl)-6-phenyl-1H-indazol-1-yl]-1-piperidinecarboxylate; intermediates | SMITHKLINE BEECHAM CORPORATION | 2008-10-23 | — | — | US | disclosed |
| US-20080262040-A1 | novel indazole carboxamide derivatives for inflammatory and tissue repair disorders like rheumatoid arthritis, asthma, and COPD; kinase inhibitors in particular IKK2; 1,1-dimethylethyl-4-[4-(aminocarbonyl)-6-phenyl-1H-indazol-1-yl]-1-piperidinecarboxylate; intermediates | SMITHKLINE BEECHAM CORPORATION | 2008-10-23 | — | — | US | disclosed |
| WO-2007102883-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262040-A1 | novel indazole carboxamide derivatives for inflammatory and tissue repair disorders like rheumatoid arthritis, asthma, and COPD; kinase inhibitors in particular IKK2; 1,1-dimethylethyl-4-[4-(aminocarbonyl)-6-phenyl-1H-indazol-1-yl]-1-piperidinecarboxylate; intermediates | IRAK2, NFKBIA, IRAK1 | GPR119 1844/4885NR3C1 675/4885USP30 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.